Growth Factors
IGF-1 LR3
Insulin-like growth factor-1 LR3
Long R3 Insulin-like Growth Factor-1
Research context
IGF-1 LR3 carries an arginine substitution at position 3 and a 13-residue N-terminal extension. Published characterisation reports substantially reduced affinity for IGF binding proteins relative to native IGF-1 — the property that makes it useful in cell culture where binding-protein interference confounds results.
Common assays: IGF-1R binding · IGFBP affinity comparison · Cell proliferation assays
Specification
| Designation | Insulin-like growth factor-1 LR3 |
|---|---|
| Full name | Long R3 Insulin-like Growth Factor-1 |
| Sequence | 83-residue IGF-1 analogue with Arg3 substitution and 13-residue N-terminal extension |
| CAS number | 946870-92-4 |
| Molecular formula | C400H625N111O115S9 |
| Molecular weight | 9111.00 g/mol |
| Formats | 10 mL Vial |
| Solubility | Dilute acetic acid; limited solubility at neutral pH |
| Storage | Lyophilised: −20 °C. Reconstituted: 2–8 °C, use promptly. |
Published literature
Selected peer-reviewed references describing research involving this compound. Listed for reference only; inclusion is not a claim about any outcome.
- Francis GL, Ross M, Ballard FJ, et al.Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potencyJournal of Molecular Endocrinology · 1992 Find on PubMed ↗
Common questions
Why is IGF-1 LR3 used in cell culture rather than native IGF-1?
Its reduced affinity for IGF binding proteins means less interference from binding proteins present in serum-containing media, giving more consistent receptor engagement.
Why does IGF-1 LR3 require acidic solvent?
Solubility is poor at neutral pH. Dilute acetic acid is standard for stock preparation, with dilution into buffer immediately before use.
Components, blends and pathway
Related compounds
CJC-1295
GHRH analog
A tetrasubstituted analogue of growth hormone-releasing hormone (1-29), studied in pituitary secretion research.
CJC-1295 / Ipamorelin
GH Blend
A prepared blend pairing a GHRH analogue with a selective ghrelin receptor secretagogue.
Tesamorelin
GHRH analog
A stabilised 44-residue GHRH analogue carrying an N-terminal hexenoyl modification.